Key result
Clopidogrel-based DAT shows no benefit over aspirin-based DAT for 12-month NACE with OAC.
Why the study?
Current guidelines recommend double antithrombotic therapy with an oral anticoagulant plus clopidogrel following brief triple therapy in AF patients undergoing PCI, but evidence on aspirin as an alternative to clopidogrel within double antithrombotic therapy remains limited.
Does aspirin-based double antithrombotic therapy (OAC plus aspirin) result in different 12-month net adverse clinical events compared to clopidogrel-based double antithrombotic therapy (OAC plus clopidogrel) in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Cohort (n=445)
Yes
Does aspirin-based double antithrombotic therapy (OAC plus aspirin) result in different 12-month net adverse clinical events compared to clopidogrel-based double antithrombotic therapy (OAC plus clopidogrel) in patients with atrial fibrillation undergoing percutaneous coronary intervention?
In a real-world cohort of atrial fibrillation patients undergoing PCI, double antithrombotic therapy using aspirin plus an oral anticoagulant resulted in similar 12-month net adverse clinical events compared to standard clopidogrel plus an oral anticoagulant.
Answers are grounded in this paper and cite their sources.
Aspirin-based DAT remains in contemporary use for AF-PCI; leaves open whether it matches clopidogrel efficacy or safety in randomized settings.
BACKGROUND: In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), current guidelines recommend a brief period of triple antithrombotic therapy (TAT) consisting of an oral anticoagulant (OAC), aspirin and clopidogrel, followed by double antithrombotic therapy (DAT) with OAC plus clopidogrel. Evidence on aspirin as an alternative to clopidogrel within DAT remains limited. AIMS: The present analysis aimed at describing contemporary use of aspirin- versus clopidogrel-based DAT and to compare 12-month clinical outcomes. METHODS: In this multicenter, observational study, consecutive patients with AF undergoing PCI between January 2019 and December 2023 and discharged on DAT with OAC plus aspirin or clopidogrel were included. The primary endpoint was the 12-month incidence of net adverse clinical events (NACE), composite of all-cause death, non-fatal myocardial infarction (MI), non-fatal stroke, urgent revascularization, and major bleeding. Secondary composite and individual endpoints were also assessed. Multivariable logistic regression was used to adjust for baseline imbalances. RESULTS: Among 445 patients, 291 (65.4%) were discharged on clopidogrel-based DAT and 154 (34.6%) on aspirin-based DAT. Baseline characteristics were largely comparable. NACE occurred in 15.1% versus 13.6% of patients (OR 1.13, 95% CI 0.64-1.98; p = 0.674), with no significant difference after multivariable adjustment (adjusted OR 1.15, 95% CI 0.59-2.26; p = 0.677). No significant between group differences were observed for secondary composite or individual efficacy and safety endpoints. CONCLUSIONS: In this real-world cohort of AF patients undergoing PCI, aspirin- and clopidogrel-based DAT with OAC were not associated with significantly different 12-month outcomes. These hypothesis-generating findings require confirmation in adequately powered randomized trials.
No takes yet. Share an insight, caveat, or question.
Panevino et al. (2026) conducted a cohort in Atrial fibrillation undergoing percutaneous coronary intervention (n=445). Clopidogrel-based double antithrombotic therapy (with oral anticoagulant) vs. Aspirin-based double antithrombotic therapy (with oral anticoagulant) was evaluated on 12-month incidence of net adverse clinical events (NACE), a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, urgent revascularization, and major bleeding (adjusted OR 1.15, 95% CI 0.59-2.26, p=0.677). Clopidogrel-based vs aspirin-based double antithrombotic therapy with OAC showed no significant difference in 12-month NACE.
Synapse has enriched 10 related papers. Consider them for comparative context: